1. US FDA, Center for Drug Evaluation and Research. Guidance for industry. Bioavailability and bioequivalence studies for orally administered drug products: general considerations. 2003. Available at: http://www.fda.gov/downloads/Drugs/Guidances/ucm070124.pdf . Accessed 24 Mar 2015.
2. Boehm G, Yao L, Han L, Zheng Q. Development of the generic drug industry in the US after the Hatch-Waxman Act of 1984. Acta Pharmaceutica Sinica B. 2013;3(5):297–311.
3. US FDA. Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA. Dec 2013. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM377465.pdf . Accessed 24 Mar 2015.
4. US FDA. Postmarketing surveillance of generic drug usage and substitution patterns (U01). RFA-FD-13-022. 8 Apr 2013. Available at: http://grants.nih.gov/grants/guide/rfa-files/RFA-FD-13-022.html . Accessed 24 Mar 2015.
5. Buehler G. Citizen’s petition response re: docket no. FDA-2007-P-0418. 7 May 2008. Available at: http://www.pharmamedtechbi.com/~/media/Images/Publications/Archive/The%20Pink%20Sheet/70/021/00700210007/fda_letter_to_cobalt.pdf . Accessed 24 Mar 2015.